http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2731342-C9
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9054ab5cdae502fc10ac1389ce339482 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-20034 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10343 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-20022 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-215 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-215 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 |
| filingDate | 2020-08-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-10-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_85df916f115ccd97c4291d154d341bc5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1587b6fec179e3584ee9015251d4a033 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_db5776018c9aca87bde743d34c79a763 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9441345add73167b2b8f9119a5e3d406 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_01cb1e0d802b5c07c23a498f3382eca9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e95f41fc84eac8694e1cff9d07ef36ff http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_950bcea022aea73a309cd3133436afb9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d2de90e756d622fd39e4eac25f99f7da http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba03862dcdb853579e9fd8cfe14f5e99 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_671a4788ebc069badaf23f3035bcd658 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_91c1c309c26933275c55a851340274f6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_359e48390aac971b51aa4b6cf4f08d76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a69eb5b3aaf3742dd76fcf711ee5aa4d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b5da4cc65f33a66cec9a488bd25f4d8f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_33ef9110a51614981a8576d7cb504f9b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cab4a984bdd22377d77c0178da56d73c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a4570e9981263022b7688a594b2f97ef http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f67eb876aee2585132987551d17bf264 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_515104d3d6b03043b8399e52ec8cd889 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_303ea84af6557493bd718d636b0ec8b4 |
| publicationDate | 2021-10-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2731342-C9 |
| titleOfInvention | Pharmaceutical agent and method for use thereof for inducing specific immunity to virus of severe acute respiratory syndrome sars-cov-2 (embodiments) |
| abstract | FIELD: biotechnology.SUBSTANCE: invention refers to biotechnology, immunology and virology. There is created a pharmaceutical agent for inducing specific immunity to the virus of severe acute respiratory syndrome SARS-CoV-2, containing component 1 representing an agent in form of an expression vector based on the recombinant human adenovirus genotype of 26thserotype in which the E1 and E3 regions are deleted, and the ORF6-Ad26 region is replaced by ORF6-Ad5, with an inbuilt expression cassette selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and containing component 2, which is an agent in the form of an expression vector based on the genome of recombinant human adenovirus strain of 5thserotype in which E1 and E3 regions are deleted, with an inbuilt expression cassette selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3. Also, a pharmaceutical agent for inducing specific immunity to the virus of severe acute respiratory syndrome SARS-CoV-2, containing component 1, which is an agent in form of an expression vector based on the genome of the recombinant human adenovirus strain of 26thserotype, in which the E1 and E3 regions are deleted, and the ORF6-Ad26 region is replaced by ORF6-Ad5, with an inbuilt expression cassette selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, as well as containing component 2, which is agent in form of expression vector based on recombinant strain of simian adenovirus 25thserotype genome, in which the E1 and E3 regions are deleted, with an inbuilt expression cassette selected from SEQ ID NO: 4, SEQ ID NO: 2, SEQ ID NO: 3. There is also created a pharmaceutical agent for inducing specific immunity to the virus of severe acute respiratory syndrome SARS-CoV-2, containing component 1, representing an agent in the form of an expression vector based on the genome of the recombinant strain of simian adenovirus of 25thserotype, in which the E1 and E3 regions are deleted, with an inbuilt expression cassette selected from SEQ ID NO: 4, SEQ ID NO: 2, SEQ ID NO: 3, as well as containing component 2, which is an agent in form of an expression vector based on genome of human recombinant strain of human adenovirus of 5thserotype, in which E1 and E3 regions are deleted, with an inbuilt expression cassette selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3. Each pharmaceutical agent is in a liquid or lyophilised form, and component 1 and component 2 are in different packages. Each pharmaceutical agent is used to induce specific immunity to the virus of severe acute respiratory syndrome SARS-CoV-2, wherein component 1 and 2 are used in an effective amount sequentially with an interval of not less than 1 week.EFFECT: invention provides development of reactions of humoral and cellular immune response against SARS-CoV-2, thus providing increased level of immune response against virus SARS-CoV-2.8 cl, 15 dwg, 4 tbl, 15 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022197209-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2761904-C1 |
| priorityDate | 2020-08-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 451.